Tags

Type your tag names separated by a space and hit enter

Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial.
Psychopharmacology (Berl). 2019 Jun; 236(6):1949-1957.P

Abstract

OBJECTIVE

This study examined the effect of adjunctive telmisartan on body metabolism in clozapine- or olanzapine-treated patients with schizophrenia.

METHOD

Each subject had been on stable dose of olanzapine or clozapine for at least 1 month. In a 12-week randomized, double-blind, placebo-controlled study, subjects received either telmisartan (80 mg once per day) or placebo. The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated based on fasting blood levels of insulin and glucose. Fasting blood levels of triglycerides and cholesterols, as well as serum levels of high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were measured. The whole-body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline and repeated at week 12.

RESULTS

Fifty-four subjects were randomized and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). There were no significant differences between the two groups in week 12 changes for HOMA-IR or fasting triglycerides (- 0.18 ± 1.24 vs 0.39 ± 1.39, p = 0.181; - 26 ± 76 vs - 10 ± 81 mg/dL, p = 0.679, respectively) (telmisartan vs placebo). Further, there were no significant between group differences in week 12 changes for other fasting lipids, body weight, body mass index, waist circumference, as well as various measures of lipid particles (p's > 0.100). The DXA assessment showed no significant differences between the two groups in week 12 changes for fat mass, lean mass, or total mass (p's > 0.100).

CONCLUSION

In the present study, adjunctive treatment of telmisartan did not seem to improve body metabolism in schizophrenia patients receiving olanzapine or clozapine. The implications for future studies were discussed. CLINICALTRIALS.

GOV IDENTIFIER

NCT00981526.

Authors+Show Affiliations

Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA. xiaoduo.fan@umassmed.edu.Department of Medicine, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA.Psychotic Disorders Program, University of Massachusetts Medical School/UMass Memorial Medical Center, Worcester, MA, 01605, USA.Schizophrenia Program, Massachusetts General Hospital/Harvard Medical School, Boston, MA, USA.Department of Psychiatry, New York University Medical School and Nathan Kline Institute, New York, NY, USA.Department of Psychiatry, Boston University/Boston Medical Center, Boston, MA, USA.

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

30747254

Citation

Fan, Xiaoduo, et al. "Adjunctive Telmisartan Treatment On Body Metabolism in Clozapine or Olanzapine Treated Patients With Schizophrenia: a Randomized, Double Blind, Placebo Controlled Trial." Psychopharmacology, vol. 236, no. 6, 2019, pp. 1949-1957.
Fan X, Copeland P, Nawras S, et al. Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology (Berl). 2019;236(6):1949-1957.
Fan, X., Copeland, P., Nawras, S., Harrington, A., Freudenreich, O., Goff, D. C., & Henderson, D. C. (2019). Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. Psychopharmacology, 236(6), 1949-1957. https://doi.org/10.1007/s00213-019-5181-z
Fan X, et al. Adjunctive Telmisartan Treatment On Body Metabolism in Clozapine or Olanzapine Treated Patients With Schizophrenia: a Randomized, Double Blind, Placebo Controlled Trial. Psychopharmacology (Berl). 2019;236(6):1949-1957. PubMed PMID: 30747254.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Adjunctive telmisartan treatment on body metabolism in clozapine or olanzapine treated patients with schizophrenia: a randomized, double blind, placebo controlled trial. AU - Fan,Xiaoduo, AU - Copeland,Paul, AU - Nawras,Shukair, AU - Harrington,Amy, AU - Freudenreich,Oliver, AU - Goff,Donald C, AU - Henderson,David C, Y1 - 2019/02/12/ PY - 2018/05/30/received PY - 2019/01/28/accepted PY - 2019/2/13/pubmed PY - 2019/10/29/medline PY - 2019/2/13/entrez KW - Body composition KW - Inflammation KW - Lipids KW - Schizophrenia KW - Telmisartan SP - 1949 EP - 1957 JF - Psychopharmacology JO - Psychopharmacology (Berl.) VL - 236 IS - 6 N2 - OBJECTIVE: This study examined the effect of adjunctive telmisartan on body metabolism in clozapine- or olanzapine-treated patients with schizophrenia. METHOD: Each subject had been on stable dose of olanzapine or clozapine for at least 1 month. In a 12-week randomized, double-blind, placebo-controlled study, subjects received either telmisartan (80 mg once per day) or placebo. The homeostasis model of assessment of insulin resistance (HOMA-IR) was calculated based on fasting blood levels of insulin and glucose. Fasting blood levels of triglycerides and cholesterols, as well as serum levels of high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6) were measured. The whole-body dual-energy X-ray absorptiometry (DXA) was used to assess body composition. Lipid particles were assessed using nuclear magnetic resonance (NMR) spectroscopy. All assessments were conducted at baseline and repeated at week 12. RESULTS: Fifty-four subjects were randomized and 43 completed the study (22 in the telmisartan group, 21 in the placebo group). There were no significant differences between the two groups in week 12 changes for HOMA-IR or fasting triglycerides (- 0.18 ± 1.24 vs 0.39 ± 1.39, p = 0.181; - 26 ± 76 vs - 10 ± 81 mg/dL, p = 0.679, respectively) (telmisartan vs placebo). Further, there were no significant between group differences in week 12 changes for other fasting lipids, body weight, body mass index, waist circumference, as well as various measures of lipid particles (p's > 0.100). The DXA assessment showed no significant differences between the two groups in week 12 changes for fat mass, lean mass, or total mass (p's > 0.100). CONCLUSION: In the present study, adjunctive treatment of telmisartan did not seem to improve body metabolism in schizophrenia patients receiving olanzapine or clozapine. The implications for future studies were discussed. CLINICALTRIALS. GOV IDENTIFIER: NCT00981526. SN - 1432-2072 UR - https://www.unboundmedicine.com/medline/citation/30747254/Adjunctive_telmisartan_treatment_on_body_metabolism_in_clozapine_or_olanzapine_treated_patients_with_schizophrenia:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://dx.doi.org/10.1007/s00213-019-5181-z DB - PRIME DP - Unbound Medicine ER -